Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExoPowder is an exosome-based biologic product developed by Evomed (Suzhou EVMedpro Technology Co., Ltd.). It is a powder-form formulation of exosomes designed for research and potential therapeutic applications, offering improved stability and ease of storage compared to liquid formulations. Exosomes are extracellular vesicles that mediate intercellular communication by transferring proteins, lipids, and nucleic acids between cells. Evomed utilizes a suite of proprietary technologies—ExoPlus, ExoCell, ExoPure, and ExoTest—to produce and characterize these exosome products. While the company does not maintain a traditional clinical pipeline with specific disease indications, ExoPowder is positioned as a high-potency raw material or finished product for use in regenerative medicine, aesthetics, and other clinical research fields.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ExoPowder.